Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.965 USD | -6.50% | -0.75% | -57.21% |
Financials (USD)
Sales 2024 * | 15.25M | Sales 2025 * | 11.36M | Capitalization | 502M |
---|---|---|---|---|---|
Net income 2024 * | -224M | Net income 2025 * | -260M | EV / Sales 2024 * | 2.84 x |
Net cash position 2024 * | 459M | Net cash position 2025 * | 228M | EV / Sales 2025 * | 24.2 x |
P/E ratio 2024 * |
-2.23
x | P/E ratio 2025 * |
-2.1
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.3% |
Latest transcript on Verve Therapeutics, Inc.
1 day | -6.50% | ||
1 week | -0.75% | ||
Current month | -0.75% | ||
1 month | -10.44% | ||
3 months | -54.43% | ||
6 months | -49.15% | ||
Current year | -57.21% |
Managers | Title | Age | Since |
---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 21-11-28 |
Andrew Ashe
PSD | President | 57 | 18-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 17-12-31 |
Lonnel Coats
BRD | Director/Board Member | 58 | 22-08-07 |
Michael MacLean
BRD | Director/Board Member | 58 | 21-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.13% | 2 M€ | -25.75% | ||
3.54% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 5.98 | -6.27% | 2,189,494 |
24-05-16 | 6.38 | +2.41% | 2,139,757 |
24-05-15 | 6.23 | 0.00% | 1,254,733 |
24-05-14 | 6.23 | +0.16% | 1,494,031 |
24-05-13 | 6.22 | +3.49% | 1,723,340 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.21% | 502M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- VERV Stock